Silexion Therapeutics Corp

SLXNCIK 0002022416 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K/A filed May 19, 2026. Sentiment + YoY language diff vs prior year. Read sections →

Signal:Neutral

Risk Factors: not detected

MD&A: not detected

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

Recent 8-K announcements

Per-item disclosure feed. Item 2.02 is the earnings release.

May 29, 20263.03 · Material Modification to Rights5.03 · Amendments to Articles8.01 · Other Events9.01 · Financial Statements and Exhibits May 26, 20268.01 · Other Events9.01 · Financial Statements and Exhibits May 18, 2026no items parsed May 15, 2026no items parsed May 14, 2026no items parsed

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Silexion Therapeutics Corp

Name	Roles	Filings
Shirvan Mitchell	Officer	2
Hadar Ilan	OfficerDirector	1
Horenshtein Hadar Mirit	Officer	1
Levin Ilan	Director10% Owner	1
Moringa Sponsor, LP	10% Owner	1

Showing 6-10 of 10

Per pagePrevPage 2 of 2

All filings

15 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
Dec 31, 2025	Peled Amnon Director	AGrant	661	$0.00	$0

Filed		Top transaction	Shares	Price	Value